Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 15Leiomyoma 4Myofibroma 2Endometriosis 2Uterine Neoplasms 1Uterine Hemorrhage 1Prostate Adenocarcinoma 1Pregnancy Complications 1Pathologic Complete Response 1Neoplasm, Residual 1Neoplasm Metastasis 1Myoma 1Metastatic Hormone-sensitive Prostate Cancer (mHSPC) 1Menorrhagia 1Adenocarcinoma 1

Interventions

enzalutamide 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Biopsy 2relugolix 1luprolide acetate gel depot 1gallium 68 PSMA-11 1abiraterone 1X-Rays 1Radium-223 1Radiotherapy, Image-Guided 1Radiotherapy 1Radiation 1Prednisone 1Lymph Node Excision 1Glutamate Carboxypeptidase II 1Abiraterone Acetate 12-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Prostate Adenocarcinoma × relugolix × Clear all
NCT06499870 2026-06-05

Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial

Northwestern University

Phase 2 Recruiting
50 enrolled
Genitourinary

Prostate Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡